Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. The company leverages its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. Its pipeline includes QINLOCK® for gastrointestinal stromal tumor (GIST) and vimseltinib for tenosynovial giant cell tumor (TGCT).